Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results

por Hong, Jin-Bon, Wu, Po-Yuan, Qin, Albert, Huang, Yi-Wen, Tseng, Kuan-Chiao, Lai, Ching-Yu, Chan, Wing-Kai, Fang, Jane, Cutler, David L., Tsai, Tsen-Fang
Publicado 2022

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B

por Huang, Yi-Wen, Hsu, Chao-Wei, Lu, Sheng-Nan, Yu, Ming-Lung, Su, Chien-Wei, Su, Wei-Wen, Chien, Rong-Nan, Hsu, Ching-Sheng, Hsu, Shih-Jer, Lai, Hsueh-Chou, Qin, Albert, Tseng, Kuan-Chiao, Chen, Pei-Jer
Publicado 2020

Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study

por Dai, Ming-Shen, Chao, Ta-Chung, Chiu, Chang-Fang, Lu, Yen-Shen, Shiah, Her-Shyong, Jackson, Christopher G. C. A., Hung, Noelyn, Zhi, Jianguo, Cutler, David L., Kwan, Rudolf, Kramer, Douglas, Chan, Wing-Kai, Qin, Albert, Tseng, Kuan-Chiao, Hung, Cheung Tak, Chao, Tsu-Yi
Publicado 2023

Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy

por Lin, Hsien‐Hong, Hsu, Shih‐Jer, Lu, Sheng‐Nan, Chuang, Wan‐Long, Hsu, Chao‐Wei, Chien, Rong‐Nan, Yang, Sien‐Sing, Su, Wei‐Wen, Wu, Jaw‐Ching, Lee, Tzong‐Hsi, Peng, Cheng‐Yuan, Tseng, Kuan‐Chiao, Qin, Albert, Huang, Yi‐Wen, Chen, Pei‐Jer
Publicado 2021

A Phase 3 clinical trial validating the potency and safety of an innovative, extra‐long‐acting interferon in chronic hepatitis C

por Chen, Chi‐Yi, Chuang, Wan‐Long, Qin, Albert, Zhang, Wen‐Hua, Zhu, Li‐Ying, Zhang, Guo‐Qiang, Chen, Jyh‐Jou, Lo, Ching‐Chu, Zhou, Xinmin, Mao, Xiaorong, Shang, Jia, Kuo, Hsing‐Tao, Xie, Wen, Chen, Chien‐Hung, Lo, Gin‐Ho, Jun, Dae W, Dang, Shuangsuo, Tsai, Chan‐Yen, Wang, Ting‐Fang, Lai, Hsin‐Hui, Tseng, Kuan‐Chiao, Huang, Yi‐Wen, Chen, Pei‐Jer
Publicado 2022